New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran − Treatment with Vutrisiran Led to 37- 49% Lower Rates of ...
− Cardiovascular Magnetic Resonance (CMR) and Echocardiographic Analyses Demonstrate that Treatment with Vutrisiran Resulted in Significant Changes on Multiple Functional and Structural Cardiac ...
CAMBRIDGE, Mass., March 29, 2025--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced moderated poster presentations of new data from ...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA ® (vutrisiran), an RNAi ...
(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) announced that results from the HELIOS-B Phase 3 study of AMVUTTRA (vutrisiran) for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) ...
A randomized, clinical trial testing vutrisiran, a small-interfering RNA (siRNA) therapy for the treatment of cardiomyopathy resulting from transthyretin amyloidosis (ATTR-CM), has met its primary ...
− Sustained Benefit of Vutrisiran Across Mortality, Cardiovascular Events, Quality of Life and Cardiac Biomarkers Observed Through Up to 48 Months, Including 12 Months from the Ongoing Open-Label ...
− Vutrisiran Treatment Led to Maintenance or Improvement in Functional Capacity, Health Status, and Quality of Life, Compared to Placebo – “The HELIOS-B study continues to deliver a robust data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results